These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23947979)

  • 1. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.
    Greenberg D; Hammerman A; Vinker S; Shani A; Yermiahu Y; Neumann PJ
    Value Health; 2013; 16(5):842-7. PubMed ID: 23947979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments.
    Kozminski MA; Neumann PJ; Nadler ES; Jankovic A; Ubel PA
    Med Decis Making; 2011; 31(3):380-5. PubMed ID: 21088130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria.
    Iskrov G; Greenberg D; Yakimov I; Cholakova H; Stefanov R
    Value Health Reg Issues; 2019 Sep; 19():157-162. PubMed ID: 31109901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary survey of oncologists' perceptions of quality of life information.
    Bezjak A; Ng P; Taylor K; MacDonald K; Depetrillo AD
    Psychooncology; 1997 Jun; 6(2):107-13. PubMed ID: 9205968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
    Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
    Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
    Long EF; Swain GW; Mangi AA
    Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
    Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
    Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.
    Rogers JG; Bostic RR; Tong KB; Adamson R; Russo M; Slaughter MS
    Circ Heart Fail; 2012 Jan; 5(1):10-6. PubMed ID: 22052901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population.
    Dilla T; Lizan L; Paz S; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Sacristán JA
    Patient Prefer Adherence; 2016; 10():1-7. PubMed ID: 26719677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
    King JT; Tsevat J; Lave JR; Roberts MS
    Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Economic evaluation of targeted cancer therapy].
    Ikeda S
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):967-70. PubMed ID: 23986036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
    Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
    Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
    Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.